RESULTS ROUND-UP: Strong US performance boosts Bard; Varian has befuddling Q4
This article was originally published in Clinica
CR Bard had a good third quarter marked by “strong underlying US growth,” according to Jefferies analyst Raj Denhoy. Overall, Q3 sales grew 9% to $830m, $11m higher than analysts had expected. US revenues increased 13% year-on-year to $565.4m, while Bard was also helped by another royalty payment from rival Gore of $38m.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.